“While smoking cessation should always be recommended as a primary step to reduce the risk of cardiovascular events, these data raise the possibility that IPE treatment may reduce the excess cardiovascular risks in patients with a history of smoking, or current smokers, and other CV risk factors.” MoreĭUBLIN, Ireland and BRIDGEWATER, N.J., Aug. These data were presented today during an Oral Abstract session at the European Society of Cardiology (ESC) Congress 2022 in Barcelona, Spain and published in EHJ Cardiovascular Pharmacotherapy.1 “These REDUCE-IT subgroup data provide us with valuable insight into the role IPE may play in helping reduce the risk of cardiovascular events in patients with a history of smoking to levels observed in those who are never-smokers,” said Michael Miller, M.D., cardiologist and Chief of Medicine, Corporal Michael J Crescenz Veterans Affairs Medical Center and Vice Chair of Medicine, Hospital of the University of Pennsylvania in Philadelphia. IPE treatment reduced the incidence of CV events in current smokers by 23.8% and former smokers by 23.0% to levels observed in never smokers (25.7%) in the placebo group. In this post hoc exploratory analysis of REDUCE-IT, icosapent ethyl (IPE) treatment significantly reduced the risk of fist and total (first and subsequent) primary composite events (CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina) in current/former smokers by 23% and in former smokers by 29%, compared to patients who were assigned to placebo.
28, 2022 (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ:AMRN) today announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking.
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers AMRN -2.31% Amarin Corporation plc Sun, Augat 4:51 AM In this article: AMRN -2.31% Watchlist Watchlist Recommendation Rating Hold Amarin Corporation plc Amarin Corporation plc - Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis - Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular Pharmacotherapy - DUBLIN, Ireland and BRIDGEWATER, N.J., Aug.
0 kommentar(er)
